WO2009074968A3 - Method for predicting the efficacy of cancer therapy - Google Patents

Method for predicting the efficacy of cancer therapy Download PDF

Info

Publication number
WO2009074968A3
WO2009074968A3 PCT/IB2008/055252 IB2008055252W WO2009074968A3 WO 2009074968 A3 WO2009074968 A3 WO 2009074968A3 IB 2008055252 W IB2008055252 W IB 2008055252W WO 2009074968 A3 WO2009074968 A3 WO 2009074968A3
Authority
WO
WIPO (PCT)
Prior art keywords
predicting
efficacy
cancer therapy
cancer
undergone
Prior art date
Application number
PCT/IB2008/055252
Other languages
French (fr)
Other versions
WO2009074968A2 (en
Inventor
Pierre Farmer
Mauro Delorenzi
Hervé BONNEFOI
Richard Iggo
Original Assignee
Ecole Polytechnique Federale De Lausanne (Epfl)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecole Polytechnique Federale De Lausanne (Epfl) filed Critical Ecole Polytechnique Federale De Lausanne (Epfl)
Publication of WO2009074968A2 publication Critical patent/WO2009074968A2/en
Publication of WO2009074968A3 publication Critical patent/WO2009074968A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The present invention relates to a method and a kit for predicting the efficacy of cancer therapy in a subject who has undergone or is undergoing chemotherapy treatment for cancer.
PCT/IB2008/055252 2007-12-12 2008-12-12 Method for predicting the efficacy of cancer therapy WO2009074968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99696107P 2007-12-12 2007-12-12
US60/996,961 2007-12-12

Publications (2)

Publication Number Publication Date
WO2009074968A2 WO2009074968A2 (en) 2009-06-18
WO2009074968A3 true WO2009074968A3 (en) 2009-09-24

Family

ID=40711520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/055252 WO2009074968A2 (en) 2007-12-12 2008-12-12 Method for predicting the efficacy of cancer therapy

Country Status (1)

Country Link
WO (1) WO2009074968A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2291553A4 (en) 2008-05-28 2011-12-14 Genomedx Biosciences Inc Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
EP2601315A4 (en) * 2010-08-02 2014-01-29 Broad Inst Inc Prediction of and monitoring cancer therapy response based on gene expression profiling
US11035005B2 (en) 2012-08-16 2021-06-15 Decipher Biosciences, Inc. Cancer diagnostics using biomarkers
TWI582239B (en) 2013-03-11 2017-05-11 諾華公司 Markers associated with wnt inhibitors
RS62529B1 (en) 2013-07-11 2021-11-30 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
MX2017006864A (en) * 2014-12-23 2017-08-28 Genentech Inc Compositions and methods for treating and diagnosing chemotherapy-resistant cancers.
CN105092846A (en) * 2015-07-22 2015-11-25 浙江大学医学院附属邵逸夫医院 Application of THBS2(Thrombospondin-2) as rectal cancer serum marker and diagnostic kit
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US11078542B2 (en) 2017-05-12 2021-08-03 Decipher Biosciences, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
EP4298215A1 (en) * 2021-02-25 2024-01-03 Tenaya Therapeutics, Inc. Enhancer sequences specific for cardiac fibroblasts and methods of use thereof
WO2023219443A1 (en) * 2022-05-11 2023-11-16 동아대학교 산학협력단 Biomarker for metastatic bladder cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"AFFYMETRIX CATALOG; PRODUKT: HUMAN GENOME U133A ARRAY; ARRAY FINDER", AFFYMETRIX PRODUCT CATALOG, XX, XX, 1 July 2002 (2002-07-01), pages 1, XP002267612 *
BONNEFOI HERVÉ ET AL: "Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.", THE LANCET ONCOLOGY DEC 2007, vol. 8, no. 12, 14 November 2007 (2007-11-14), pages 1071 - 1078, XP002531727, ISSN: 1474-5488 *
CLEATOR SUSAN J ET AL: "The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.", BREAST CANCER RESEARCH : BCR 2006, vol. 8, no. 3, 2006, pages R32, XP002531723, ISSN: 1465-542X *
FARMER P ET AL: "A stroma-related gene signature predicts resistance to epirubicin-containing neoadjuvant chemotherapy in breast cancer", BREAST CANCER RESEARCH AND TREATMENT, vol. 106, no. Suppl. 1, 3 November 2007 (2007-11-03), & 30TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA; DECEMBER 13 -16, 2007, pages S11, XP002531722, ISSN: 0167-6806 *
KÖNINGER JÖRG ET AL: "Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 JUL 2004, vol. 10, no. 14, 15 July 2004 (2004-07-15), pages 4776 - 4783, XP002531725, ISSN: 1078-0432 *
NEWTON TANYA R ET AL: "Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer", INTERNATIONAL JOURNAL OF CANCER, vol. 119, no. 4, August 2006 (2006-08-01), pages 875 - 883, XP002531724, ISSN: 0020-7136 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, UK, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *
WEST ROBERT B ET AL: "Determination of stromal signatures in breast carcinoma", PLOS BIOLOGY, vol. 3, no. 6, June 2005 (2005-06-01), pages 1101 - 1110, XP002531726, ISSN: 1544-9173(print) 1545-7885(ele *

Also Published As

Publication number Publication date
WO2009074968A2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
WO2009074968A3 (en) Method for predicting the efficacy of cancer therapy
WO2008076278A3 (en) Methods of cancer treatment with igf1r inhibitors
EP1991701A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
MX2010009724A (en) Methods of treating inflammatory pain.
ZA200906765B (en) Combination therapies comprising quinoxaline inhibitors of P13K-Alpha for use in the treatment of cancer
MX2010009722A (en) Methods of treating chronic pain.
IL208027A0 (en) Methods, compositions, and kits for treating pain and pruritus
WO2008003007A3 (en) Compositions and methods for treating parasitic infections
EP2173740A4 (en) Heme-oxygenase inhibitors and use of the same in the treatment of cancer and diseases of the central nervous system
EP1774043A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2171086A4 (en) Methods of diagnosing and treating cancer
PT2101731T (en) Endoxifen for use in the treatment of cancer
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
EP2049151A4 (en) Methods and compositions for the treatment of cancer
WO2009093213A3 (en) Method for predicting and diagnosing brain tumor
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
EP2295598A4 (en) Method and kit for detection of cancer, and therapeutic agent for cancer
EP2012798A4 (en) Use of inositol-tripyrophosphate in treating tumors and diseases
WO2010119126A3 (en) Diagnostic methods and tools to predict the efficacy of targeted agents against igf-1 pathway activation in cancer
WO2012073047A3 (en) Compositions and methods
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
EP2164990A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
TN2009000490A1 (en) Cancer treatment combination therapy comprising vinflunine and trastuzumab
EP2370819A4 (en) Diagnostic and treatment methods for cancer based on immune inhibitors
WO2008052054A3 (en) Synergism between activated immune cells and conventional cancer therapies

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859041

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 08859041

Country of ref document: EP

Kind code of ref document: A2